Great Novel Therapeutics Biotech & Medicals
Great Novel Therapeutics Biotech & Medicals engages in the development of drugs for the treatment of advanced and refractory cancers. The company develops drugs for cancer immunotherapy, including tumor microenvironment regulators, epigenetic immunoactivators, and immune-regulating multi-kinase inhibitors. The company was formerly known as GNT Biotech & Medicals Corporation. Great Novel Therapeut… Read more
Great Novel Therapeutics Biotech & Medicals (7427) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of June 2025: -0.088x
Based on the latest financial reports, Great Novel Therapeutics Biotech & Medicals (7427) has a cash flow conversion efficiency ratio of -0.088x as of June 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (NT$-49.74 Million) by net assets (NT$563.86 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Great Novel Therapeutics Biotech & Medicals - Cash Flow Conversion Efficiency Trend (2019–2024)
This chart illustrates how Great Novel Therapeutics Biotech & Medicals's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Great Novel Therapeutics Biotech & Medicals Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Great Novel Therapeutics Biotech & Medicals ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
International Integrated Systems, Inc.
TW:6614
|
0.393x |
|
BEIJING UR.C.D.+DEV.GRP H
F:BDG
|
N/A |
|
Ovostar Union N.V.
WAR:OVO
|
0.029x |
|
U.S. GoldMining Inc. Common stock
NASDAQ:USGO
|
-0.754x |
|
Sinkang Industries Co Ltd
TW:2032
|
-0.005x |
|
Valartis Group AG
SW:VLRT
|
-0.010x |
|
Exicom Tele-Systems Limited
NSE:EXICOM
|
-0.010x |
|
Inv Tricahue
SN:TRICAHUE
|
0.046x |
Annual Cash Flow Conversion Efficiency for Great Novel Therapeutics Biotech & Medicals (2019–2024)
The table below shows the annual cash flow conversion efficiency of Great Novel Therapeutics Biotech & Medicals from 2019 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | NT$633.32 Million | NT$-76.85 Million | -0.121x | -36.37% |
| 2023-12-31 | NT$618.04 Million | NT$-54.99 Million | -0.089x | +51.22% |
| 2022-12-31 | NT$360.80 Million | NT$-65.81 Million | -0.182x | -12.06% |
| 2021-12-31 | NT$208.35 Million | NT$-33.92 Million | -0.163x | +53.14% |
| 2020-12-31 | NT$120.55 Million | NT$-41.88 Million | -0.347x | -25.77% |
| 2019-12-31 | NT$67.00 Million | NT$-18.51 Million | -0.276x | -- |